<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Occupational asthma: Management, prognosis, and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Occupational asthma: Management, prognosis, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Occupational asthma: Management, prognosis, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine Lemière, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David I Bernstein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H603599688"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Occupational asthma (OA) is a form of work-related asthma that is characterized by variable airflow limitation, airway hyperresponsiveness, and airway inflammation induced by immunologic or nonimmunologic exposures in the work environment [<a href="#rid1">1</a>]. Work-exacerbated asthma is defined as preexisting or concurrent asthma that worsens in the workplace, but is not induced by it.</p><p>The management, prognosis, and prevention of OA will be reviewed here. The definition, epidemiology, causes, risk factors, pathogenesis, clinical features, evaluation, and diagnosis of OA, and the diagnosis and management of RADS and irritant–induced asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/538.html" rel="external">"Occupational asthma: Pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/536.html" rel="external">"Irritant-induced asthma"</a>.)</p><p class="headingAnchor" id="H293008290"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The key element is to make the diagnosis and remove the subject from exposure as quickly as possible after the onset of symptoms, as a long duration of exposure is associated with a poor prognosis of the disease. Although asthma is persistent in the majority of subjects even after removal from exposure, OA may be cured in some cases if removal from exposure occurs early following onset of symptoms. The management of OA requires a combination of avoidance of further exposure to sensitizing agents, reduction in exposure to irritant agents (eg, environmental tobacco smoke, strong fumes and fragrances, extremes of temperature and humidity) and pharmacotherapy based on the severity of asthma. The management of occupational rhinitis, which may accompany OA, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7529.html" rel="external">"Occupational rhinitis"</a>.)</p><p class="headingAnchor" id="H293008873"><span class="h2">Exposure avoidance</span><span class="headingEndMark"> — </span>Exposure avoidance is the cornerstone of management of immunologic OA [<a href="#rid2">2-7</a>]. For comparison, the role of exposure avoidance in other forms of work-related asthma is also discussed.</p><p class="headingAnchor" id="H111252"><span class="h3">Immunologic occupational asthma</span><span class="headingEndMark"> — </span>The most important intervention after identification of immunologic OA is prompt removal of the worker from further exposure to the sensitizing agent. Patients with OA generally have progressive deterioration in lung function if they remain in the working environment [<a href="#rid8">8-10</a>], and fatal cases have occurred among workers with ongoing workplace exposure to either high-molecular-weight or low-molecular-weight provocative antigens [<a href="#rid11">11</a>]. A description of high and low-molecular-weight agents is provided separately  (<a class="graphic graphic_table graphicRef66185" href="/z/d/graphic/66185.html" rel="external">table 1</a>). Every year new agents causing immunologic OA are identified [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Causative agents'</a>.)</p><p>Systematic reviews that assessed the outcome of immunologic OA indicate that complete and definitive removal from exposure to the causal agent is the optimal treatment for immunologic OA [<a href="#rid13">13,14</a>]. Workers with immunologic OA who remain exposed to their causal agent are at high risk of experiencing asthma exacerbations. Workers with persistent OA may develop bronchospasm with exposure to nonspecific asthma triggers due to bronchial hyperresponsiveness. Thus, the management plan should also include avoidance of other asthma triggers (eg, environmental tobacco smoke, extremes of heat and cold) at and away from work. (See  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a>.)</p><p class="headingAnchor" id="H111259"><span class="h3">Irritant-induced asthma</span><span class="headingEndMark"> — </span>Workers with nonimmunologic, irritant-induced asthma may be able to continue to work if the risk of a high-level exposure to the inciting agent is reduced by use of appropriate engineering controls and respiratory protective devices [<a href="#rid15">15</a>]. Due to the irritant nature of the inciting agent, low dose exposures are less likely to cause an increase in symptoms, compared with immunologic inciting agents. Chronic exposure to irritant agents may contribute to work-related asthma [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/536.html" rel="external">"Irritant-induced asthma", section on 'Treatment'</a>.) </p><p class="headingAnchor" id="H111266"><span class="h3">Work-exacerbated asthma</span><span class="headingEndMark"> — </span>For workers with work-exacerbated asthma, avoidance of asthma triggers both at work and away from work (eg, environmental tobacco smoke, indoor allergens, extremes of heat and cold) is important together with the use of appropriate medications to control asthma symptoms. In general, as long as these goals are achieved, the worker need not change jobs or leave the work environment. (See  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a>.)</p><p class="headingAnchor" id="H953617198"><span class="h2">Exposure reduction</span><span class="headingEndMark"> — </span>Reducing exposure to the causal agent, rather than complete avoidance represents a substantially less satisfactory approach in terms of respiratory outcome, compared with complete avoidance or removal. </p><p>In one systematic review, a reduction in exposure was associated with a lower likelihood of improvement or resolution of asthma symptoms and a higher risk of worsening of the symptoms and nonspecific bronchial hyperresponsiveness compared with complete avoidance [<a href="#rid17">17</a>]. In another systematic review, reduction of exposure increased the likelihood of reporting absence of symptoms, but did not affect forced expiratory volume in one second (FEV<sub>1</sub>); removal from exposure was associated with an increased risk of unemployment [<a href="#rid13">13</a>].</p><p>Some workers with OA, often those with milder symptoms, may choose not to leave their workplace due to concerns about a reduction of income with job reassignment or unemployment [<a href="#rid13">13</a>]. Ongoing surveillance is advised for workers with OA who have continued low level exposure to a known causative agent. Evidence of further deterioration in asthma control or lung function should lead to renewed recommendations for complete avoidance of exposure.</p><p class="headingAnchor" id="H111823"><span class="h3">Respiratory protection devices</span><span class="headingEndMark"> — </span>Engineering and work practice controls are generally regarded as the most effective methods to control exposures to airborne hazardous substances. However, as an alternative, several respiratory protection devices (RPDs) are available to help protect workers from noxious occupational inhalants. </p><p>RPDs include air-purifying masks that filter particulates (eg, dust or particulate respirators) or chemically remove vapors or gases (eg, masks with cartridges or canisters) and powered air purifying respirators (also known as personal powered respirators, or PPRs) that supply clean air. The particular device is chosen based on the characteristics of the causative agent. These devices require proper fitting, careful removal practices, and regular maintenance. Patients with impaired pulmonary function at baseline may not tolerate the extra work of breathing resulting in suboptimal compliance with these devices. Further work is needed to evaluate efficacy with long-term use in the workplace.</p><p>Data in support of using RPDs to reduce exposure to an agent known to have caused OA are limited to a few small case series that found only partial protection when the RPD was used in workers with OA due to high [<a href="#rid18">18</a>] or low [<a href="#rid19">19</a>] molecular-weight agents or:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of a dust respirator (such as an N95 mask) was examined in two workers with OA due to buckwheat or wheat flour, one with only a late phase reaction and one with both early and late onset of asthma symptoms [<a href="#rid20">20</a>]. Both early and late reactions were suppressed when the dust respirator was worn during workplace exposure. Information about long-term efficacy of the mask was not provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of personal powered respirators (PPRs) was assessed in 26 farmers by measuring pulmonary function after work-related dust exposure in the laboratory with and without the PPR [<a href="#rid21">21</a>]. The PPR blunted the increase in airway resistance following dust exposure but did not entirely prevent it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personal powered respirators (PPR) were evaluated in 24 agricultural workers with OA [<a href="#rid22">22</a>]. Morning and evening peak expiratory flow rates and daily symptoms of the subjects were monitored for 3 months without and for 10 months with the PPR. Morning peak flow rate improved with the PPR and daily variation in the peak flow rate diminished, consistent with improved asthma control. Occupational rhinitis also improved with use of the PPR. In a separate study, eight patients with OA due to laboratory animal allergy wore a PPR (Racal Airstream) during workplace exposure for seven weeks [<a href="#rid23">23</a>]. Six of the eight patients had adequate protection based on peak flow readings and a symptom diary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A laminar flow helmet with a high efficiency air purifying (HEPA) system was tested in 10 subjects with latex-induced OA, during challenges that simulated work exposure to latex gloves [<a href="#rid24">24</a>]. The helmet with HEPA filtration was effective in preventing the asthma symptoms and fall in FEV<sub>1</sub> that occurred during challenges without the helmet. However, it is not known whether this type of protection would be adequate protection against exposure to other high-molecular-weight causative agents in a work environment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive pressure helmets can be used by workers with OA caused by low-molecular-weight agents if the duration of exposure is short. However, these protective devices are cumbersome and not well tolerated for longer intervals such as a work shift.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peak expiratory flow (PEF) monitoring was performed in twenty subjects with metal-working fluid-induced OA before and after wearing an air-fed RPD while exposed to metal-working fluid. Although there were numerically higher mean PEF values when a wearing a RPD at work, the difference was not statistically significant [<a href="#rid19">19</a>]. Several workers still showed work-related decline in PEF despite consistent use of their RPD.</p><p></p><p>Further study is needed to determine whether any form of respirator would adequately prevent inhalation of a causative agent, such that a worker with OA could continue working in the same workplace.</p><p class="headingAnchor" id="H293008866"><span class="h2">Pharmacologic treatment of asthma</span><span class="headingEndMark"> — </span>Pharmacologic treatment of OA is essentially the same as for non-occupational asthma, although it cannot replace exposure prevention [<a href="#rid3">3,4</a>]. The general goals of pharmacologic therapy for asthma and the treatment of irritant-induced asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Initiating pharmacologic treatment'</a> and  <a class="medical medical_review" href="/z/d/html/536.html" rel="external">"Irritant-induced asthma", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H111442"><span class="h3">Approach to treatment</span><span class="headingEndMark"> — </span>Initiation of pharmacologic therapy for OA follows a step-wise approach, as described for nonoccupational asthma in the NAEPP and the Global Initiative for Asthma (GINA) guidelines [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Initiating pharmacologic treatment'</a> and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p><p>The optimal duration of pharmacologic therapy for OA is unknown. We typically re-assess asthma control at 8 to 12 week intervals. When asthma control is achieved, we taper the controller medications based on perceived efficacy, presence of adverse effects, patient preference, and cost considerations. Guidelines for tapering of inhaled GCs have not been validated, but we usually decrease by 20 to 25 percent increments at one to three month intervals to a medium or low dose.</p><p class="headingAnchor" id="H839256"><span class="h3">Immunotherapy</span><span class="headingEndMark"> — </span>Subcutaneous immunotherapy (SCIT) is occasionally administered to workers with OA who are unable or unwilling to change their work environment and are sensitized to high-molecular-weight agents for which appropriate allergen extracts are available [<a href="#rid27">27</a>]. Sublingual immunotherapy (SLIT) has demonstrated benefit in allergic asthma, although not specifically in OA. However, supportive data for SCIT and SLIT are limited, particularly regarding workers with ongoing high level exposure, such as that experienced in a workplace. (See  <a class="medical medical_review" href="/z/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy", section on 'Allergic asthma'</a>.)</p><p>The evidence supporting the use of SCIT for selected patients with OA comes from a few small studies of SCIT with high-molecular-weight antigens [<a href="#rid27">27-30</a>]. As examples, two randomized trials have tested SCIT among patients with cat or dog dander-induced asthma [<a href="#rid28">28,29</a>]. In one trial, 28 subjects were assigned to cat allergen SCIT or control and noted a marked reduction in symptoms during subsequent cat exposure without any significant adverse reactions [<a href="#rid28">28</a>]. In the other trial, SCIT improved symptoms related to cat exposure but not to dog exposure. Subsequent studies have confirmed that dog SCIT requires a high maintenance dose to achieve benefit, so the absence of benefit to dog SCIT in this study may have been due to an insufficient dose [<a href="#rid31">31,32</a>]. A small study showed improvement in rhinitis, asthma, and skin symptoms with SCIT in sensitized workers exposed to rodents [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"</a>.)</p><p>Two randomized trials of SCIT administered for OA involved healthcare workers sensitized to natural rubber latex [<a href="#rid34">34,35</a>]. After specific SCIT, a significant improvement was observed in tolerance to direct exposure (glove-use test), but not in other parameters of asthma control, such as symptom scores, use of medication, or bronchial reactivity. Systemic reactions occurred in 69 percent of patients and after 8 percent of the doses [<a href="#rid35">35</a>]. However, SCIT is no longer a consideration for latex OA, as workplace practices to reduce latex exposure have subsequently improved to the point that SCIT is not needed.</p><p>In a separate trial of patients with airway symptoms due to wheat flour exposure, 18 subjects received SCIT using a wheat flour extract while 10 subjects received placebo. Treated subjects had a decrease in skin prick test sensitivity to flour and airway hyperresponsiveness along with improvement in their symptoms [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/394.html" rel="external">"Anaphylaxis induced by subcutaneous allergen immunotherapy", section on 'Background'</a> and  <a class="medical medical_review" href="/z/d/html/5554.html" rel="external">"Latex allergy: Management"</a>.)</p><p>Several factors limit the use of SCIT for OA:</p><p class="bulletIndent1"><span class="glyph">●</span>Only a few therapeutic allergen extracts are commercially available for agents that cause OA (eg, cat and dog epithelia, house dust mites, pollen, and rat and mouse epidermal extracts).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed sensitization to several allergens may also be a problem. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Combined exposures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCIT to foods, such as wheat, fish, shellfish or nuts, is not currently advised (outside of research settings) due to lack of data regarding safety or efficacy. However, a few case reports and case series have supported the use of SCIT to wheat extracts for bakers with OA [<a href="#rid15">15,27,30,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic reactions have required modification or discontinuation of SCIT among many workers with OA [<a href="#rid35">35,37</a>], and the risk of severe systemic reactions may be greater among these patients due to their high level of allergen exposure [<a href="#rid34">34,38</a>]. SCIT is not advisable in patients with uncontrolled or severe asthma due to increased risk of life-threatening systemic allergic reactions [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCIT, using low-molecular-weight allergens, has not been tested due to concerns about toxicity [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCIT has no role in the management of OA caused by corrosive or irritative substances.</p><p></p><p class="headingAnchor" id="H3027660898"><span class="h3">Biologic therapies</span></p><p class="headingAnchor" id="H839354"><span class="h4">Anti-IgE therapy</span><span class="headingEndMark"> — </span>Anti-immunoglobulin (Ig) E therapy is typically indicated for patients with moderate-to-severe persistent asthma, demonstrable sensitivity to a perennial aeroallergen, and incomplete symptom control despite high dose inhaled glucocorticoid and a long-acting beta agonist. However, it is considered experimental therapy for OA, pending additional research on efficacy and safety. When caring for a patient with poorly-controlled OA, the strong recommendation would be for complete avoidance of the causative agent, rather than anti-IgE therapy. (See <a class="local">'Immunologic occupational asthma'</a> above.)</p><p>For patients who may be candidates for anti-IgE therapy, elevation of serum total IgE and specific IgE to the causative workplace allergen must be documented. Dosing and monitoring of anti-IgE therapy are described separately. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Administration'</a>.)</p><p>The use of anti-IgE therapy (<a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>) has been described in a few patients with poorly-controlled asthma despite guideline-based pharmacologic therapy who were unable to change their work environment [<a href="#rid37">37,38,40,41</a>]. In the largest series, 10 patients with severe, uncontrolled OA due to high and low molecular weight agents were treated with anti-IgE therapy and concomitant reduction in workplace exposures [<a href="#rid41">41</a>]. Nine patients exhibited lower rates of exacerbation and a reduced requirement for oral or inhaled glucocorticoids, although two of these eventually left the workplace. As the study was not controlled, the relative contributions of workplace modifications and anti-IgE therapy to the observed improvement in asthma control are not known. </p><p>For patients with OA who have left the workplace, the indications for anti-IgE therapy are the same as for those with asthma not related to occupational exposure. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Indications and patient selection'</a>.)</p><p>The follow-up of asthmatic patients who are removed from exposure does not differ from asthmatic patients without OA. There is no published recommendation regarding the monitoring of patients who remain exposed to the offending agent at their workplace. However, it appears reasonable to perform at least a yearly follow-up including spirometry of those patients to ensure that their asthma remains adequately controlled. The frequency of assessment needs to be tailored according to their asthma severity and control. Whether or not a yearly monitoring of airway responsiveness/inflammation can provide guidance on a complete removal from exposure by detecting a worsening asthma in this population has never been studied.</p><p class="headingAnchor" id="H2742742298"><span class="h4">Anti-IL-5 and anti-IL4/13 therapies</span><span class="headingEndMark"> — </span>A multicenter European cohort of 997 subjects with OA showed that 162 (16.2 percent) met criteria for severe asthma [<a href="#rid42">42</a>]. Of these, 20 to 25 percent had clinical characteristics (eg, blood or sputum eosinophilia) suggesting they could benefit from a biologic therapy, such as anti-interleukin (IL)-5 (<a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>), anti-IL-5 receptor alpha (<a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>), or anti-IL-4 receptor alpha subunit (<a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>) treatment [<a href="#rid43">43</a>]. However, to our knowledge, the efficacy of these agents has not been investigated systematically in this population. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'</a>.)</p><p class="headingAnchor" id="H111509"><span class="h1">DISABILITY</span><span class="headingEndMark"> — </span>Workers with severe occupational asthma (OA) may be unable to work for several months or longer even after cessation of exposure to the culprit agent. The assessment of disability is based on the degree of bronchial obstruction and hyperresponsiveness as well as the need for anti-asthma medication for assuring control. The criteria for and evaluation of pulmonary disability in the United States are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2791.html" rel="external">"Disability assessment and determination in the United States"</a> and  <a class="medical medical_review" href="/z/d/html/6966.html" rel="external">"Evaluation of pulmonary disability"</a>.) </p><p class="headingAnchor" id="H293008297"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Improvement of occupational asthma (OA) is typically gradual after cessation of exposure and reaches a plateau after approximately two years [<a href="#rid44">44</a>], although some studies suggest that further improvement may occur later at slower rates [<a href="#rid45">45,46</a>]. Most patients show incomplete resolution of asthma, airway responsiveness, and inflammation, even many years following cessation of exposure [<a href="#rid47">47</a>]. However, a shorter duration of exposure prior to removal from the workplace may be associated with a higher rate of resolution of sensitization and bronchial hyperresponsiveness [<a href="#rid48">48-50</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of OA studies (1681 participants) with a median duration of follow-up of 31 (range 6 to 240) months, complete recovery from asthma was noted in approximately 32 percent (95% CI 26-38 percent), while bronchial hyperresponsiveness was persistent in approximately 73 percent (95% CI 66-79 percent) of subjects [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 997 participants with OA, 162 were classified as having severe OA [<a href="#rid42">42</a>]. Severe OA was associated with persistent exposure to the causal agent (odds ratio 2.78, 95% CI 1.50-5.60), longer duration of disease, lower educational level, childhood asthma, and sputum production. Among those with severe asthma despite cessation of exposure, obesity was identified as a potentially modifiable risk factor.</p><p></p><p>Even if asthma control improves with complete avoidance of exposure to the sensitizing agent, approximately one-half of workers with OA have persistent problems with depression and anxiety that are more severe than patients with a similar severity of non-work-related asthma [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H293008304"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Control of the level of exposure to workplace respiratory sensitizers can reduce the number of workers who become sensitized and is the most important method of primary prevention [<a href="#rid18">18,53</a>]. The efficacy of reducing exposure levels has been demonstrated for acid anhydrides, detergent enzymes, isocyanates, laboratory animals, and latex [<a href="#rid54">54-59</a>]. As examples, a threshold for flour exposure of 0.2 mcg/m<sup>3</sup> has led to a reduction in the risk of sensitization [<a href="#rid60">60</a>], and the incidence of occupational asthma (OA) due to isocyanates has decreased in association with better workplace exposure practices [<a href="#rid61">61,62</a>].</p><p>The use of respiratory protective equipment (RPE) decreases worker exposure levels and reduces the incidence, but does not completely protect against development of OA [<a href="#rid18">18,63</a>]. As an example, among 66 new hires at a plant using hexahydrophthalic anhydride, the use of RPE was associated with a decrease in the rate of developing occupational respiratory disease, including OA, from 10 to 2 percent [<a href="#rid64">64</a>].</p><p>Exposure monitoring, combined with medical surveillance of exposed workers, enables early identification of sensitization and removal from exposure for those who develop OA [<a href="#rid65">65-67</a>]. Continuous monitoring of ambient levels of several low-molecular-weight chemicals, including isocyanates and formaldehyde, is now available. In addition, immunochemical techniques have been developed for quantifying ambient levels of high-molecular-weight allergens. Unfortunately, the very low concentration of antigen required to provoke bronchospasm once sensitization has occurred is often below the limits of detection.</p><p>Because of the low predictive value of atopy for the development of OA and because nearly 50 percent of young adults are atopic, atopic subjects should not be excluded from high-risk workplaces. However, atopic individuals who enter high-risk workplaces with ambient exposure to protein allergens (eg, detergent enzymes) require regular follow-up examinations for early detection of sensitization and/or bronchial hyperresponsiveness. Diagnostic models including work-related respiratory symptoms, allergic symptoms, and characteristics of the job may be helpful to predict the occurrence of OA among bakers at high risk of sensitization to bakery allergens [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Atopy'</a>.) </p><p>Smoking cessation should be advised for general health reasons and may also decrease the risk of antigenic sensitization in the workplace [<a href="#rid18">18,69</a>].</p><p>It may be possible in the future to screen chemicals for their potential to induce respiratory allergy prior to their introduction into industry because studies have shown that the capacity for a chemical to cause sensitization is related to its structure [<a href="#rid70">70,71</a>].</p><p class="headingAnchor" id="H4211360094"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112673.html" rel="external">"Society guideline links: Occupational asthma"</a>.)</p><p class="headingAnchor" id="H293008677"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposure avoidance</strong> – For patients who are diagnosed with occupational asthma (OA) induced by a sensitizing agent, the most important intervention is prompt and complete removal of the worker from further exposure. Patients with OA generally have progressive deterioration in lung function if they remain in the working environment. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As an exception, for workers with mild OA (mild symptoms and minimal physiologic impairment) who have a strong preference for remaining in the workplace, reducing exposure via engineering controls or respiratory protective devices may be effective, but evidence is conflicting and "safe" levels of exposure have not been established. Careful ongoing surveillance is advised to detect any further deterioration in lung function. (See <a class="local">'Exposure reduction'</a> above and <a class="local">'Respiratory protection devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy</strong> – Pharmacologic treatment of OA follows the same guidelines as nonoccupational asthma but cannot replace exposure prevention. (See <a class="local">'Approach to treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Initiating pharmacologic treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic and immunotherapy</strong> – For the majority of patients with OA, there is insufficient evidence of benefit in the setting of ongoing workplace exposure to advise the use of either biologic therapy (eg, anti-IgE, anti-IL-5/IL-5R, anti-IL-4R) or subcutaneous immunotherapy (SCIT).</p><p></p><p class="bulletIndent1">However, for most workers who have OA caused by sensitization to house dust mite, cat, or dog allergens and unavoidable workplace exposure, we suggest SCIT with the appropriate extract (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). As an exception, workers whose asthma is uncontrolled or severe should not receive SCIT because they are at increased risk of injection-related anaphylaxis. (See <a class="local">'Immunotherapy'</a> above and <a class="local">'Anti-IgE therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy", section on 'Severe or unstable asthma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Improvement of OA after cessation of exposure is typically gradual and reaches a plateau approximately two years after cessation of exposure. Most patients show incomplete resolution of asthma, airway responsiveness, and inflammation, even many years following cessation of exposure. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – For many occupational sensitizers, control of the level of exposure to the sensitizing agent reduces the number of workers who become sensitized and is the most important method of prevention. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H30297083"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Moira Chan-Yeung, MD and Jean-Luc Malo, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Bernstein IL, Bernstein DI, Chan-Yeung M, Malo JL. Definition and classification of asthma in the workplace. In: Asthma in  the workplace, 4th ed, Malo JL, Chan-Yeung M, Bernstein DI (Eds), CRC Press, Boca Raton, FL 2013. p.1-5.</li><li><a class="nounderline abstract_t">Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280.</a></li><li><a class="nounderline abstract_t">Fishwick D, Barber CM, Bradshaw LM, et al. Standards of care for occupational asthma: an update. Thorax 2012; 67:278.</a></li><li><a class="nounderline abstract_t">Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J 2012; 39:529.</a></li><li><a class="nounderline abstract_t">Kim M-H, Jung J-W, Kang H-R. The Usefulness of Job Relocation and Serum Eosinophil Cationic Protein in Baker's Asthma. Int Arch Allergy Immunol 2013; 161:252.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med 2014; 370:640.</a></li><li><a class="nounderline abstract_t">Descatha A, Leproust H, Choudat D, et al. Factors associated with severity of occupational asthma with a latency period at diagnosis. Allergy 2007; 62:795.</a></li><li><a class="nounderline abstract_t">Cote J, Kennedy S, Chan-Yeung M. Outcome of patients with cedar asthma with continuous exposure. Am Rev Respir Dis 1990; 141:373.</a></li><li><a class="nounderline abstract_t">Moscato G, Dellabianca A, Perfetti L, et al. Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999; 115:249.</a></li><li><a class="nounderline abstract_t">Pisati G, Baruffini A, Zedda S. Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure. Br J Ind Med 1993; 50:60.</a></li><li><a class="nounderline abstract_t">Ortega HG, Kreiss K, Schill DP, Weissman DN. Fatal asthma from powdering shark cartilage and review of fatal occupational asthma literature. Am J Ind Med 2002; 42:50.</a></li><li><a class="nounderline abstract_t">Cartier A. New causes of immunologic occupational asthma 2014-2020. Curr Opin Allergy Clin Immunol 2021; 21:110.</a></li><li><a class="nounderline abstract_t">Henneberger PK, Patel JR, de Groene GJ, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2019; 10:CD006308.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Dressel H, Nowak D, et al. What is the optimal management option for occupational asthma? Eur Respir Rev 2012; 21:97.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.</a></li><li><a class="nounderline abstract_t">Dumas O, Le Moual N. Do chronic workplace irritant exposures cause asthma? Curr Opin Allergy Clin Immunol 2016; 16:75.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Dressel H, Wilken D, et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. Eur Respir J 2011; 38:804.</a></li><li><a class="nounderline abstract_t">Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62:290.</a></li><li><a class="nounderline abstract_t">Ilgaz A, Moore VC, Robertson AS, et al. Occupational asthma; the limited role of air-fed respiratory protective equipment. Occup Med (Lond) 2019; 69:329.</a></li><li><a class="nounderline abstract_t">Obase Y, Shimoda T, Mitsuta K, et al. Two patients with occupational asthma who returned to work with dust respirators. Occup Environ Med 2000; 57:62.</a></li><li><a class="nounderline abstract_t">Müller-Wening D, Neuhauss M. Protective effect of respiratory devices in farmers with occupational asthma. Eur Respir J 1998; 12:569.</a></li><li><a class="nounderline abstract_t">Taivainen AI, Tukiainen HO, Terho EO, Husman KR. Powered dust respirator helmets in the prevention of occupational asthma among farmers. Scand J Work Environ Health 1998; 24:503.</a></li><li><a class="nounderline abstract_t">Slovak AJ, Orr RG, Teasdale EL. Efficacy of the helmet respirator in occupational asthma due to laboratory animal allergy (LAA). Am Ind Hyg Assoc J 1985; 46:411.</a></li><li><a class="nounderline abstract_t">Laoprasert N, Swanson MC, Jones RT, et al. Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions. J Allergy Clin Immunol 1998; 102:998.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on June 27, 2017).</li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Moscato G, Pala G, Sastre J. Specific immunotherapy and biological treatments for occupational allergy. Curr Opin Allergy Clin Immunol 2014; 14:576.</a></li><li><a class="nounderline abstract_t">Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860.</a></li><li><a class="nounderline abstract_t">Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77:478.</a></li><li><a class="nounderline abstract_t">Armentia A, Martin-Santos JM, Quintero A, et al. Bakers' asthma: prevalence and evaluation of immunotherapy with a wheat flour extract. Ann Allergy 1990; 65:265.</a></li><li><a class="nounderline abstract_t">Lent AM, Harbeck R, Strand M, et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006; 118:1249.</a></li><li><a class="nounderline abstract_t">Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007; 119:872.</a></li><li><a class="nounderline abstract_t">Goddard AG, Azar AE. Work-related asthma secondary to IgE-mediated reactions to rodents successfully treated with immunotherapy. Ann Allergy Asthma Immunol 2016; 117:556.</a></li><li><a class="nounderline abstract_t">Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106:585.</a></li><li><a class="nounderline abstract_t">Sastre J, Fernández-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.</a></li><li><a class="nounderline abstract_t">Armentia A, Arranz M, Martin JM, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. Ann Allergy 1992; 69:441.</a></li><li><a class="nounderline abstract_t">Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.</a></li><li><a class="nounderline abstract_t">Pérez Pimiento A, Bueso Fernández A, García Loria J, et al. Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 2008; 18:490.</a></li><li><a class="nounderline abstract_t">Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.</a></li><li><a class="nounderline abstract_t">Olivieri M, Biscardo CA, Turri S, Perbellini L. Omalizumab in persistent severe bakers' asthma. Allergy 2008; 63:790.</a></li><li><a class="nounderline abstract_t">Lavaud F, Bonniaud P, Dalphin JC, et al. Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 2013; 68:813.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Godet J, Hurdubaea L, et al. Severe Occupational Asthma: Insights From a Multicenter European Cohort. J Allergy Clin Immunol Pract 2019; 7:2309.</a></li><li><a class="nounderline abstract_t">Smith AM, Sastre J. The Role of Immunotherapy and Biologic Treatments in Occupational Allergic Disease. J Allergy Clin Immunol Pract 2020; 8:3322.</a></li><li><a class="nounderline abstract_t">Malo JL, Cartier A, Ghezzo H, et al. Patterns of improvement in spirometry, bronchial hyperresponsiveness, and specific IgE antibody levels after cessation of exposure in occupational asthma caused by snow-crab processing. Am Rev Respir Dis 1988; 138:807.</a></li><li><a class="nounderline abstract_t">Perfetti L, Cartier A, Ghezzo H, et al. Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: relevance of the length of the interval from cessation of exposure. Chest 1998; 114:398.</a></li><li><a class="nounderline abstract_t">Malo JL, Ghezzo H. Recovery of methacholine responsiveness after end of exposure in occupational asthma. Am J Respir Crit Care Med 2004; 169:1304.</a></li><li><a class="nounderline abstract_t">Maghni K, Lemière C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004; 169:367.</a></li><li><a class="nounderline abstract_t">Gautrin D, Ghezzo H, Infante-Rivard C, et al. Long-term outcomes in a prospective cohort of apprentices exposed to high-molecular-weight agents. Am J Respir Crit Care Med 2008; 177:871.</a></li><li><a class="nounderline abstract_t">Rachiotis G, Savani R, Brant A, et al. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax 2007; 62:147.</a></li><li><a class="nounderline abstract_t">Miedinger D, Malo JL, Ghezzo H, et al. Factors influencing duration of exposure with symptoms and costs of occupational asthma. Eur Respir J 2010; 36:728.</a></li><li><a class="nounderline abstract_t">Yacoub MR, Lavoie K, Lacoste G, et al. Assessment of impairment/disability due to occupational asthma through a multidimensional approach. Eur Respir J 2007; 29:889.</a></li><li><a class="nounderline abstract_t">Malo JL, Boulet LP, Dewitte JD, et al. Quality of life of subjects with occupational asthma. J Allergy Clin Immunol 1993; 91:1121.</a></li><li><a class="nounderline abstract_t">Cullinan P, Tarlo S, Nemery B. The prevention of occupational asthma. Eur Respir J 2003; 22:853.</a></li><li><a class="nounderline abstract_t">Liss GM, Bernstein D, Genesove L, et al. Assessment of risk factors for IgE-mediated sensitization to tetrachlorophthalic anhydride. J Allergy Clin Immunol 1993; 92:237.</a></li><li><a class="nounderline abstract_t">Cathcart M, Nicholson P, Roberts D, et al. Enzyme exposure, smoking and lung function in employees in the detergent industry over 20 years. Medical Subcommittee of the UK Soap and Detergent Industry Association. Occup Med (Lond) 1997; 47:473.</a></li><li><a class="nounderline abstract_t">Drexler H, Schaller KH, Nielsen J, et al. Efficacy of measures of hygiene in workers sensitised to acid anhydrides and the influence of selection bias on the results. Occup Environ Med 1999; 56:202.</a></li><li><a class="nounderline abstract_t">Fisher R, Saunders WB, Murray SJ, Stave GM. Prevention of laboratory animal allergy. J Occup Environ Med 1998; 40:609.</a></li><li><a class="nounderline abstract_t">Allmers H, Schmengler J, Skudlik C. Primary prevention of natural rubber latex allergy in the German health care system through education and intervention. J Allergy Clin Immunol 2002; 110:318.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Easty A, Eubanks K, et al. Outcomes of a natural rubber latex control program in an Ontario teaching hospital. J Allergy Clin Immunol 2001; 108:628.</a></li><li><a class="nounderline abstract_t">Malo JL, Chan-Yeung M. Agents causing occupational asthma. J Allergy Clin Immunol 2009; 123:545.</a></li><li><a class="nounderline abstract_t">McDonald JC, Keynes HL, Meredith SK. Reported incidence of occupational asthma in the United Kingdom, 1989-97. Occup Environ Med 2000; 57:823.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med 2002; 59:58.</a></li><li><a class="nounderline abstract_t">Petsonk EL, Wang ML, Lewis DM, et al. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118:1183.</a></li><li><a class="nounderline abstract_t">Grammer LC, Harris KE, Yarnold PR. Effect of respiratory protective devices on development of antibody and occupational asthma to an acid anhydride. Chest 2002; 121:1317.</a></li><li><a class="nounderline abstract_t">Fishwick D, Barber CM, Bradshaw LM, et al. Standards of care for occupational asthma. Thorax 2008; 63:240.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Liss GM. Prevention of occupational asthma. Curr Allergy Asthma Rep 2010; 10:278.</a></li><li><a class="nounderline abstract_t">Wild DM, Redlich CA, Paltiel AD. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occup Environ Med 2005; 62:743.</a></li><li><a class="nounderline abstract_t">Jonaid BS, Rooyackers J, Stigter E, et al. Predicting occupational asthma and rhinitis in bakery workers referred for clinical evaluation. Occup Environ Med 2017; 74:564.</a></li><li><a class="nounderline abstract_t">Siracusa A, Marabini A, Folletti I, Moscato G. Smoking and occupational asthma. Clin Exp Allergy 2006; 36:577.</a></li><li><a class="nounderline abstract_t">Graham C, Rosenkranz HS, Karol MH. Structure-activity model of chemicals that cause human respiratory sensitization. Regul Toxicol Pharmacol 1997; 26:296.</a></li><li><a class="nounderline abstract_t">Jarvis J, Seed MJ, Elton R, et al. Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds. Occup Environ Med 2005; 62:243.</a></li></ol></div><div id="topicVersionRevision">Topic 15718 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bernstein IL, Bernstein DI, Chan-Yeung M, Malo JL. Definition and classification of asthma in the workplace. In: Asthma in  the workplace, 4th ed, Malo JL, Chan-Yeung M, Bernstein DI (Eds), CRC Press, Boca Raton, FL 2013. p.1-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860754" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156958" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Standards of care for occupational asthma: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379148" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for the management of work-related asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Usefulness of Job Relocation and Serum Eosinophil Cationic Protein in Baker's Asthma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521110" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573728" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factors associated with severity of occupational asthma with a latency period at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689129" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcome of patients with cedar asthma with continuous exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925092" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381658" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12111690" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fatal asthma from powdering shark cartilage and review of fatal occupational asthma literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332925" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : New causes of immunologic occupational asthma 2014-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31593318" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Workplace interventions for treatment of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22654081" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : What is the optimal management option for occupational asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779187" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914673" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Do chronic workplace irritant exposures cause asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436354" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837849" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence based guidelines for the prevention, identification, and management of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269209" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Occupational asthma; the limited role of air-fed respiratory protective equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711271" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Two patients with occupational asthma who returned to work with dust respirators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762781" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Protective effect of respiratory devices in farmers with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988093" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Powered dust respirator helmets in the prevention of occupational asthma among farmers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050677" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of the helmet respirator in occupational asthma due to laboratory animal allergy (LAA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847441" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847441" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115685" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Specific immunotherapy and biological treatments for occupational allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291281" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950252" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2221484" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bakers' asthma: prevalence and evaluation of immunotherapy with a wheat flour extract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157654" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immunologic response to administration of standardized dog allergen extract at differing doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292953" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Advances in upper airway diseases and allergen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27614679" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Work-related asthma secondary to IgE-mediated reactions to rodents successfully treated with immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984382" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743562" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1456487" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767458" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of omalizumab in health care workers with occupational latex allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19123449" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of omalizumab treatment in a baker with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Allergen immunotherapy: a practice parameter third update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445199" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Omalizumab in persistent severe bakers' asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23647648" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Usefulness of omalizumab in ten patients with severe occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30914232" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe Occupational Asthma: Insights From a Multicenter European Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32781049" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Role of Immunotherapy and Biologic Treatments in Occupational Allergic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3202454" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patterns of improvement in spirometry, bronchial hyperresponsiveness, and specific IgE antibody levels after cessation of exposure in occupational asthma caused by snow-crab processing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726721" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: relevance of the length of the interval from cessation of exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070824" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recovery of methacholine responsiveness after end of exposure in occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578217" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Airway inflammation after cessation of exposure to agents causing occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18218991" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term outcomes in a prospective cohort of apprentices exposed to high-molecular-weight agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040933" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Outcome of occupational asthma after cessation of exposure: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150200" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Factors influencing duration of exposure with symptoms and costs of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182649" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Assessment of impairment/disability due to occupational asthma through a multidimensional approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509574" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Quality of life of subjects with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14621096" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The prevention of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8349934" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Assessment of risk factors for IgE-mediated sensitization to tetrachlorophthalic anhydride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9604480" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Enzyme exposure, smoking and lung function in employees in the detergent industry over 20 years. Medical Subcommittee of the UK Soap and Detergent Industry Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448330" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy of measures of hygiene in workers sensitised to acid anhydrides and the influence of selection bias on the results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675719" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevention of laboratory animal allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12170275" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Primary prevention of natural rubber latex allergy in the German health care system through education and intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590392" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Outcomes of a natural rubber latex control program in an Ontario teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18951622" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Agents causing occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11077011" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reported incidence of occupational asthma in the United Kingdom, 1989-97.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836470" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035694" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948068" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of respiratory protective devices on development of antibody and occupational asthma to an acid anhydride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17905825" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Standards of care for occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424999" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevention of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234399" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Surveillance for isocyanate asthma: a model based cost effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314756" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Predicting occupational asthma and rhinitis in bakery workers referred for clinical evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650041" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Smoking and occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9441920" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Structure-activity model of chemicals that cause human respiratory sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778257" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
